Objective: To examine the clinical efficacy of bevacizumab (BEV) combined with temozolomide (TMZ) as a treatment for patients with recurrent malignant gliomas.
Methods: 50 patients with recurrent malignant gliomas treated at our hospital between January 2019 and January 2022 were enrolled and randomized to the control group and combine group using a random table method, with 25 cases in each group. The control group received TMZ and the combine group received BEV plus TMZ. The disease control rate (DCR), the quality-of-life score before and after treatment, and the median 6-month progression-free survival (PFS) rate as well as adverse reactions were recorded and compared.
Results: There was a significant difference in DCR between the combine group (80%) and the control group (52%) (χ2 = 5.556, P = .018). In each of the quality-of-life scales, the scores of the combine group were significantly greater than those of the control group after treatment, and the difference was statistically significant (P < .05). In the control group, the median PFS was 16.2 weeks, and the six-month PFS was 19.8%. However, in the combine group, the median PFS was 21.9 weeks, and the six-month PFS was 43.1% (P < .05). Comparing the two groups, the rate of adverse reactions in the control group was significantly higher (44.0% vs 12.0%) (χ2 = 6.349, P = .012).
Conclusion: BEV plus TMZ is remarkable in the treatment of patients with recurrent malignant gliomas. The combination treatment improves the DCR and PFS of patients and their quality of life, and does not increase adverse reactions, making it a promising approach that deserves widespread promotion and clinical application.